CEO Outlook: The future of pharma with Audrey Derveloy, Novartis Ireland

As a young science graduate, Audrey Derveloy’s goal was to have a positive impact on society. Now, as a leader of a global medicines company during a world-wide pandemic, that dream is being realised.  

Novartis employs 1,400 people in Ireland, and the company uses innovative science and digital technologies to create transformative treatments in areas of great medical need such as Cardiology, Oncology and Immunology. Having spent several years in leadership roles at Novartis in France, Audrey was offered the role of General Manager and Country President of Novartis Ireland in early 2020, just before the COVID-19 pandemic began.  

In this episode of The EY CEO Outlook Podcast, Audrey Derveloy, General Manager of Novartis Ireland, tells host Richard Curran about her aspirations as a young medical student, her lifelong love of science, moving her family to Ireland to run Novartis’ operations there, and her vision for the future of medicine.

They also discuss: 

·        Why COVID-19 is a valuable opportunity to build trust in the Pharma sector 

·        Novartis’ footprint in Ireland and what kind of medicines it makes in this country 

·        Why the future of Pharma lies in intelligent data 

·        Audrey’s views on improving Irelands’ Pharma regulatory landscape  

·        Why the State may need to collaborate more with the pharma sector to develop innovative medicines.